Reduction of oxidative stress marker levels by anti-TNF-α antibody, infliximab, in patients with rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 26, Issue 1, 2008, Pages 73-80

  Kageyama, Yasunori ^a   Takahashi, Masaaki ^a   Ichikawa, Tetsuya ^a   Torikai, Eiji ^a   Nagano, Akira ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Infliximab; Reactive oxygen species; Rheumatoid arthritis

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ADVANCED GLYCATION END PRODUCT; C REACTIVE PROTEIN; DNA; INFLIXIMAB; ISOPROSTANE; METHOTREXATE; PENTOSIDINE; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE MARKER; DNA DAMAGE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; LIPID PEROXIDATION; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTAGLANDIN URINE LEVEL; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARGININE; ARTHRITIS, RHEUMATOID; DEOXYGUANOSINE; DNA DAMAGE; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; ISOPROSTANES; LIPID PEROXIDATION; LYSINE; MALE; MIDDLE AGED; REACTIVE OXYGEN SPECIES;

EID: 40749105734     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. AREND WP, DAYER J-M: Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum 1995; 38: 151-60.
2. ZHANG HG, HYDE K, PAGE GP et al.: Novel tumor necrosis factor alpha-regulated genes in rheumatoid arthritis. Arthritis Rheum 2004; 50: 420-31.
3. PALEOLOG EM, YOUNG S, STARK AC et al.: Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1258-65.
4. FELDMANN M, MAINI RN: Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Ann Rev Immunol 2001; 19: 163-96.
5. KAGEYAMA Y, TAKAHASHI M, TORIKAI E et al.: Treatment with anti-TNF-alpha antibody infliximab reduces serum IL-15 levels in patients with rheumatoid arthritis. Clin Rheumatol 2007; 26: 505-9.
6. HITCHON CA, EL-GABALAWY HS: Oxidation in rheumatoid arthritis. Arthritis Res Ther 2004; 6:265-78.
7. HALLIWELL B: Oxygen radicals, nitric oxide and human inflammatory joint disease. Ann Rheum Dis 1995; 54: 505-10.
8. KUMAR DA, RAJU KY, SETTU K, KUMANAN K, PUVANAKRISHNAN R: Effect of a derivatized tetrapeptide from lactoferrin on nitric oxide mediated matrix metalloproteinase-2 production by synovial fibroblasts in collagen-induced arthritis in rats. Peptides 2006; 27: 1434-42.
9. BIEMOND P, SWAAK AJ, KOSTER JF: Protective factors against oxygen free radicals and hydrogen peroxide in rheumatoid arthritis synovial fluid. Arthritis Rheum 1984; 27: 760-5.
10. WOO CH, KIM TB, CHOI JA et al.: Inhibition of receptor internalization attenuates the TNF alpha-induced ROS generation in non-phagocytic cells. Biochem Biophys Res Commun 2006; 351: 972-8.
11. SAKON S, XUE X, TAKEKAWA M et al.: NF-kappaB inhibits TNF-induced accumulation of ROS that mediate prolonged MAPK activation and necrotic cell death. EMBO J 2003; 22: 3898-909.
12. MIESEL R, MURPHY MP, KROGER H: Enhanced mitochondrial radical production in patients which rheumatoid arthritis correlates with elevated levels of tumor necrosis factor alpha in plasma. Free Radic Res 1996; 25: 161-9.
13. MUR E, ZABERNIGG A, HILBE W, EISTERER W, HALDER W, THALER J: Oxidative burst of neutrophils in patients with rheumatoid arthritis: Influence of various cytokines and medication. Clin Exp Rheumatol 1997; 15: 233-7.
14. DANG PM, STENSBALLE A, BOUSSETTA T et al.: A specific p47phox-serine phosphorylated by convergent MAPKs mediates neutrophil NADPH oxidase priming at inflammatory sites. J Clin Invest 2006; 116: 2033-43.
15. JIKIMOTO T, NISHIKUBO Y, KOSHIBA M et al.: Thioredoxin as a biomarker for oxidative stress in patients with rheumatoid arthritis. Mol Immunol 2002; 38: 765-72.
16. HELMERSSON J VESSBY B, LARSSON A: Association of type 2 diabetes with cyclooxygenase-mediated inflammation and oxidative stress in an elderly population. Circulation 2004; 109: 1729-34.
17. 2 alpha levels are elevated in individuals with non-insulin dependent diabetes mellitus. FEBS Lett 1995; 368: 225-9.
18. HALLIWELL B, HOULT JR, BLAKE DR: Oxidants, inflammation, and anti-inflammatory drugs. FASEB J 1988; 2: 2867-73.
19. TAKAHASHI M: Pentosidine, an Advanced Glycation Endproduct, and Arthritis. Current Rheumatology Reviews 2006; 2: 319-24.
20. RALL LC, ROUBENOFF R, MEYDANI SN, HAN SN, MEYDANI M: Urinary 8-hydroxy-2′-deoxyguanosine (8-OHdG) as a marker of oxidative stress in rheumatoid arthritis and aging: Effect of progressive resistance training. J Nutr Biochem 2000 11: 581-4.
21. JASWAL S, MEHTA HC, SOOD AK, KAUR J: Antioxidant status in rheumatoid arthritis and role of antioxidant therapy. Clin Chim Acta 2003; 338: 123-9.
22. 2 isoprostanes in hypercholesterolemia. Circulation 1998; 98: 2785-7.
23. BASU S, WHITEMAN M, MATTEY DL, HALLIWELL B: Raised levels of F2-isoprostanes and prostaglandin F2a in different rheumatic diseases. Ann Rheum Dis 2001; 60: 627-31.
24. ARNETT FC, EDWORTHY SM, BLOCH DA et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
25. TAKAHASHI M, HOSHINO H, KUSHIDA K, KAWANA K, INOUE T: Direct quantification of pentosidine urine and serum by HPLC with column switching. Clin Chem 1996; 42: 1439-44.
26. FIRUZI O, FUKSA L, SPADARO C et al.: Oxidative stress parameters in different systemic rheumatic diseases. J Pharm Pharmacol 2006; 58: 951-7.
27. PILLINGER MH, ABRAMSON SB: The neutrophil in rheumtoid arthritis. Rheum Dis Clin North Am 1995; 21: 691-714.
28. WINROW VR, WINYARD PG, MORRIS CJ, BLAKE DR: Free radicals in inflammation: Second messengers and mediators of tissue destruction. Br Med Bull 1993; 49: 506-22.
29. MAPP PI, GROOTVELD MC, BLAKE DR: Hypoxia, oxidative stress and rheumatoid arthritis. Br Med Bull 1995; 51: 419-36.
30. BATES EJ, JOHNSON CC, LOWTHER DA: Inhibition of proteoglycan synthesis by hydrogen peroxide in cultured bovine articular cartilage. Biochim Biophys Acta 1985; 838: 221-8.
31. BAKER MS, BOLIS S, LOWTHER DA: Oxidation of articular cartilage glyceraldehyde-3-phosphate dehydrogenase (G3PDH) occurs in vivo during carrageenin-induced arthritis. Agents Actions 1991; 32: 299-304.
32. SCHALKWIJK J, VAN DEN BERG WB, VAN DE PUTTE LB, JOOSTEN LA: An experimental model for hydrogen peroxide-induced tissue damage. Effects of a single inflammatory mediator on periarticular tissues. Arthritis Rheum 1986; 29: 532-8.
33. MICHAELIS J, VISSERS MC, WINTERBOURN CC: Different effects of hypochlorous acid on human neutrophil metalloproteinases: Activation of collagenase and inactivation of collagenase and gelatinase. Arch Biochem Biophys 1992; 292: 555-62.
34. GARRETT IR, BOYCE BF, OREFFO RO, BONEWALD L, POSER L, MUNDY GR: Oxygen-derived free radicals stimulate osteoclastic bone resorption in rodent bone in vitro and in vivo. J Clin Invest 1990; 85: 632-9.
35. BAX BE, ALAM AS, BANERJI B et al.: Stimulation of osteoclastic bone resorption by hydrogen peroxide. Biochem Biophys Res Commun 1992; 183: 1153-8.
36. BONIZZI G, PIETTE J, MERVILLE MP, BOURS V: Cell type-specific role for reactive oxygen species in nuclear factor-α B activation by interleukin-1. Biochem Pharmacol 2000; 59: 7-11.
37. BONIZZI G, PIETTE J, SCHOONBROODT S et al.: Reactive oxygen intermediate-dependent NF-kappaB activation by interleukin-1beta requires 5-lipoxygenase or NADPH oxidase activity. Mol Cell Biol 1999; 19: 1950-60.
38. PITTONI V, BOMBARDIERI M, SPINELLI FR et al.: Anti-tumor necrosis factor (TNF) alpha treatment of rheumatoid arthritis (infliximab) selectively down regulates the production of interleukin (IL) 18 but not of IL12 and IL13. Ann Rheum Dis 2002; 61: 723-5.
39. DEN BROEDER AA, WANTEN GJ, OYEN WJ, NABER T, VAN RIEL PL, BARRERA P: Neutrophil migration and production of reactive oxygen species during treatment with a fully human anti-tumor necrosis factor-alpha manoclonal antibody in patients with rheumatoid arthritis. J Rheumatol 2003; 30: 232-7.
40. LEMARECHAL H, ALLANORE Y, CHENEVIER-GOBEAUX C, KAHAN A, EKINDJIAN OG, BORDERIE D: Serum protein oxidation in patients with rheumatoid arthritis and effects of infliximab therapy. Clin Chim Acta 2006; 372: 147-53.
41. RODRIGUEZ-GARCIA J, REQUENA JR, RODRIGUEZ-SEGADE S: Increased concentrations of serum pentosidine in rheumatoid arthritis. Clin Chem 1998; 44: 250-5.
42. BEISSWENGER PJ, MOORE LL, BRINCK-JOHNSEN T, CURPHEY TJ: Increased collagen-linked pentosidine levels and advanced glycosylation end products in early diabetic nephropathy. J Clin Invest 1993; 92: 212-7.
43. UCHIYAMA A, OHISHI T, TAKAHASHI M et al.: Fluorophores from aging human articular cartilage. J Biochem (Tokyo) 1991; 110: 714-8.
44. STEENVORDEN MM, HUIZINGA TW, VERZIJL N et al.: Activation of receptor for advanced glycation end products in osteoarthritis leads to increased stimulation of chondrocytes and synoviocytes. Arthritis Rheum 2006; 54: 253-63.
45. ANDERSON MM, HAZEN SL, HSU FF, HEINECKE JW: Human neutrophils employ the myeloperoxidase-hydrogen peroxide-chloride system to convert hydroxy-amino acids into glycolaldehyde, 2-hydroxypropanal, and acrolein. A mechanism for the generation of highly reactive alpha-hydroxy and alpha, beta-unsaturated aldehydes by phagocytes at sites of inflammation. J Clin Invest 1997; 99: 424-32.
46. TAKAHASHI M, KUSHIDA K, OHISHI T et al.: Quantitative analysis of crosslinks pyridinoline and pentosidine in articular cartilage of patients with bone and joint disorders. Arthritis Rheum 1994; 37: 724-8.
47. VERZIJL N, DEGROOT J, BANK RA et al.: Age-related accumulation of the advanced glycation endproduct pentosidine in human articular cartilage aggrecan: The use of pentosidine levels as a quantitative measure of protein turnover. Matrix Biol 2001; 20: 409-17.
48. TAKAHASHI M, SUZUKI M, KUSHIDA K, MIYAMOTO S, INOUE T: Relationship between pentosidine levels in serum and urine and activity in rheumatoid arthritis. Br J Rheumatol 1997; 36: 637-42.
49. HEIN GE, KOHLER F: The advanced glycaion end product pentosidine correlated to IL-6 and other relevant inflammatory markers in rheumatoid arthritis. Rheumatology Int 2005; 26: 137-41.
50. SCHRAUFSTATTER IU, HYSLOP PA, JACKSON JH, COCHRANE CG: Oxidant-induced DNA damage of target cells, J Clin invest 1988; 82: 1040-50.
51. KASAI H., CRAIN P. F., KUCHINO Y, NISHIMURA S, OOTSUYAMA A, TANOOKA H: Formation of 8-hydroxyguanine moiety in cellular DNA by agents producing oxygen radicals and evidence for its repair. Carcinogenesis (Lond.) 1986; 7: 1849-51.
52. TOYOKUNI S: Reactive oxygen species-induced molecular damage and its application in pathology. Pathol Int 1999; 49: 91-102.
53. ERHOLA M, TOYOKUNI S, OKADA K et al.: Biomarker evidence of DNA oxidation in lung cancer patients: Association of urinary 8-hydroxy-2′-deoxyguanosine excretion with radiotherapy, chemotherapy, and response to treatment. FEBS Lett 1997; 409: 287-91.
54. HONDA M, YAMADA Y, TOMONAGA M, ICHINOSE H, KAMIHIRA S: Correlation of urinary 8-hydroxy-2′-deoxyguanosine (8-OHdG), a biomarker of oxidative DNA damage, and clinical features of hematological disorders: a pilot study. Leuk Res 2000; 24: 461-8.
55. KIM JY, MUKHERJEE S, NGO LC, CHRISTIANI DC: Urinary 8-hydroxy-2′-deoxyguanosine as a biomarker of oxidative DNA damage in workers exposed to fine particulates. Environ Health Perspect 2004; 112: 666-71.
56. 2-isoprostanes) are formed in situ on phospholipids. Proc Natl Acad Sci USA 1992; 89: 10721-5.
57. MALLAT Z, PHILIP I, LEBRET M, CHATEL D, MACLOUF J, TEDGUI A: Elevated levels of 8-iso-prostaglandin F2alpha in pericardial fluid of patients with heart failure: A potential role for in vivo oxidant stress in ventricular dilatation and progression to heart failure. Circulation 1998; 28; 97: 1536-9.
58. STEIN CM, TANNER SB, AWAD JA, ROBERTS LJ 2ND, MORROW JD: Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma. Arthritis Rheum 1996; 39: 1146-50.
59. AMES PR, ALVES J, MURAT I, ISENBERG DA, NOUROOZ-ZADEH J: Oxidative stress in systemic lupus erythematosus and allied conditions with vascular involvement. Rheumatology (Oxford) 1999; 38: 529-34.
60. KAGEYAMA Y, TAKAHASHI M, NAGAFUSA T, TORIKAI E, NAGANO A: Methotrexate Reduces the Levels of Pentosidine and 8-hydroxydoxy guanosine in Patients with Rheumatoid Arthritis. Mod Rheumatol (in press).
61. THANNICKAL VJ, FANBURG BL: Reactive oxygen species in cell signaling. Am J Physiol Lung Cell Moll Physiol 2000; 279: 1005-28.
62. BAE SC, KIM SJ, SUNG MK: Inadequate antioxidant nutrient intake and altered plasma antioxidant status of rheumatoid arthritis patients. J Am Coll Nutr 2003; 22: 311-5.
63. KAMANLI A, NAZIROGLU M, AYDILEK N, HACIEVLIYAGIL C: Plasma lipid peroxidation and antioxidant levels in patients with rheumatoid arthritis. Cell Biochem Funct 2004; 22: 53-7.
64. GIUSTARINI D, LORENZINI S, ROSSI R, CHINDAMO D, SIMPLICIO PD, MARCOLONGO R: Altered thiol pattern in plasma of subjects affected by rheumatoid arthritis. Clin Exp Rheum 2005; 23: 205-12.